These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 26432074

  • 1. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q, Liu L, Zhang Y, Li X, Wu D.
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [Abstract] [Full Text] [Related]

  • 2. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L, Qu Q, Jiao W, Zhang Y, Li X, Ding C, Wu D.
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [Abstract] [Full Text] [Related]

  • 3. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H, Wang L, Li C, Wuxiao Z, Shao R, Wang H, Lu Y.
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D.
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [Abstract] [Full Text] [Related]

  • 5. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
    Liu L, Zhang Y, Jin Z, Zhang X, Zhao G, Si Y, Lin G, Ma A, Sun Y, Wang L, Wu D.
    Int J Hematol; 2014 Mar; 99(5):603-8. PubMed ID: 24623261
    [Abstract] [Full Text] [Related]

  • 6. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W, Mao L, Qian J, Qian W, Meng H, Mai W, Tong H, Tong Y, Jin J.
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [Abstract] [Full Text] [Related]

  • 7. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
    Lei M, Liu L, Wang Z, Wu D.
    Indian J Cancer; 2019 Mar; 56(2):167-172. PubMed ID: 31062738
    [Abstract] [Full Text] [Related]

  • 9. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
    Wang Y, Li W, Chen S, Qiu H, Sun A, Wu D.
    Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
    [Abstract] [Full Text] [Related]

  • 10. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH, Jiang H, Jiang B, Lu J, Jiang Q, Bao L, Zhang XH, Qin YZ, Huang XJ.
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [Abstract] [Full Text] [Related]

  • 11. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL, Cui HX, Zou JY, Xue MX, Tang XW, Zhang YM, Wu DP.
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [Abstract] [Full Text] [Related]

  • 12. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
    Zhu BG, Qian SX, Hong M, Lu H, Wu HX, Zhang SJ, Qiu HX, Xu W, Li JY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 14. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S.
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [Abstract] [Full Text] [Related]

  • 15. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX.
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):734-738. PubMed ID: 30369183
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.